These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23334071)

  • 1. Scopolamine as an antidepressant: a systematic review.
    Jaffe RJ; Novakovic V; Peselow ED
    Clin Neuropharmacol; 2013; 36(1):24-6. PubMed ID: 23334071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
    Drevets WC; Zarate CA; Furey ML
    Biol Psychiatry; 2013 Jun; 73(12):1156-63. PubMed ID: 23200525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients.
    Janowsky DS
    Curr Psychiatry Rep; 2011 Dec; 13(6):443-5. PubMed ID: 21976067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scopolamine as an antidepressant.
    Pae CU
    Clin Neuropharmacol; 2013; 36(3):102. PubMed ID: 23673916
    [No Abstract]   [Full Text] [Related]  

  • 8. The potential role of scopolamine as antidepressant for mood disorder.
    Pae CU
    Clin Neuropharmacol; 2014; 37(2):67-8. PubMed ID: 24614664
    [No Abstract]   [Full Text] [Related]  

  • 9. The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions.
    Drevets WC; Bhattacharya A; Furey ML
    Adv Pharmacol; 2020; 89():357-386. PubMed ID: 32616213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular glutamate transporter 1 (VGLUT1)-mediated glutamate release and membrane GluA1 activation is involved in the rapid antidepressant-like effects of scopolamine in mice.
    Yu H; Li M; Zhou D; Lv D; Liao Q; Lou Z; Shen M; Wang Z; Li M; Xiao X; Zhang Y; Wang C
    Neuropharmacology; 2018 Mar; 131():209-222. PubMed ID: 29274366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test.
    Pałucha-Poniewiera A; Podkowa K; Lenda T; Pilc A
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):155-161. PubMed ID: 28647535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of muscarinic receptor mechanisms in antidepressant drug action.
    Witkin JM; Smith JL; Golani LK; Brooks EA; Martin AE
    Adv Pharmacol; 2020; 89():311-356. PubMed ID: 32616212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antidepressant effects of anticholinergic drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Jun; 47(6):17-20. PubMed ID: 19585799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495.
    Podkowa K; Podkowa A; Sałat K; Lenda T; Pilc A; Pałucha-Poniewiera A
    Neuropharmacology; 2016 Dec; 111():169-179. PubMed ID: 27569995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.
    Furey ML; Drevets WC; Szczepanik J; Khanna A; Nugent A; Zarate CA
    Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25820840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scopolamine and depression: a role for muscarinic antagonism?
    Hasselmann H
    CNS Neurol Disord Drug Targets; 2014; 13(4):673-83. PubMed ID: 24938776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice.
    Singh P; Singh TG
    Indian J Pharmacol; 2015; 47(4):388-93. PubMed ID: 26288470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.